Compare UBS & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBS | PRPO |
|---|---|---|
| Founded | 1862 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6B | 32.4M |
| IPO Year | N/A | N/A |
| Metric | UBS | PRPO |
|---|---|---|
| Price | $43.21 | $25.00 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 14.6K |
| Earning Date | 10-29-2025 | 11-14-2025 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 84.33 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $48,193,000,000.00 | $22,800,000.00 |
| Revenue This Year | $4.87 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | $18.63 | ★ N/A |
| Revenue Growth | 2.09 | ★ 30.95 |
| 52 Week Low | $25.75 | $3.90 |
| 52 Week High | $43.76 | $28.50 |
| Indicator | UBS | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 77.49 | 58.24 |
| Support Level | $38.33 | $23.92 |
| Resistance Level | $38.27 | $25.62 |
| Average True Range (ATR) | 0.54 | 1.42 |
| MACD | 0.55 | -0.07 |
| Stochastic Oscillator | 91.87 | 74.25 |
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.